ErbB-targeted CAR T-cell immunotherapy of cancer

Lynsey M. Whilding*, John Maher

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Chimeric antigen receptor (CAR) based immunotherapy has been under development for the last 25 years and is now a promising new treatment modality in the field of cancer immunotherapy. The approach involves genetically engineering T cells to target malignant cells through expression of a bespoke fusion receptor that couples an HLA-independent antigen recognition domain to one or more intracellular T-cell activating modules. Multiple clinical trials are now underway in several centers to investigate CAR T-cell immunotherapy of diverse hematologic and solid tumor types. The most successful results have been achieved in the treatment of patients with B-cell malignancies, in whom several complete and durable responses have been achieved. This review focuses on the preclinical and clinical development of CAR T-cell immunotherapy of solid cancers, targeted against members of the ErbB family.

Original languageEnglish
Pages (from-to)229-241
Number of pages13
Issue number3
Publication statusPublished - 1 Mar 2015


  • cancer
  • chimeric antigen receptor
  • ErbB receptors
  • HER2
  • immunotherapy
  • T cells


Dive into the research topics of 'ErbB-targeted CAR T-cell immunotherapy of cancer'. Together they form a unique fingerprint.

Cite this